The UCLA AIDS Prevention and Treatment Clinical Trials Unit (UCLA-APT-CTU) is a multidisciplinary research unit composed of a core administrative unit and four clinical research sites in metropolitan Los Angeles. The investigative team has over 15 years of leadership experience in the design, implementation, and conduct of clinical trials evaluating both therapeutic and prevention strategies. Under the leadership of Judith Currier MD, MSc and a senior investigator team including Thomas Coates, PhD, Ronald Mitsuyasu, MD, Eric Daar, MD, Cathy Reback, Ph D, Steve Shoptaw, PhD and Stephen Brown MD, the unit will participate in the design and conduct of studies addressing the following four priority research areas; Prevention of HIV Infection, Translational Research/Drug Development, Optimization of Clinical Management, and Vaccine Research and Development in collaboration with the AIDS Clinical Trials Group (ACTG), the HIV Prevention Trials Network (HTPN) and the Vaccine Trials Network (VTN). The CTU has an administrative core and clinical research site at the UCLA Center for Clinical AIDS Research and Education (CARE Center) and additional Clinical Research Sites (CRS) at Harbor UCLA Medical Center and Friends Research Institute/Integrated Substance Abuse Program (ISAP) UCLA and AIDS Research Alliance.
The specific aims of our unit are to: 1. Evaluate new and potentially more effective HIV treatments. 2. Evaluate strategies for optimal use of antiretroviral therapies (ARV) in diverse populations. 3. Evaluate strategies to optimize the management of HIV infection and related co-morbidities. 4. Investigate HIV vaccines for therapy and for prevention of HIV infection. 5. Evaluate novel strategies for prevention of HIV infection in high-risk stimulant and injection drug users. 6. Evaluate strategies using ARV to prevent HIV acquisition. 7. Assess the role of early interventions in acutely infected individuals on long-term outcomes and transmission rates. 8. Mentor new minority investigators in cross-disciplinary HIV/AIDS research. 9. Make significant contributions to the leadership of the ACTG, HPTN and VTN through participation in the group leadership, scientific committees and protocol teams. 10. Stimulate community involvement and encourage participation of women and racial/ethnic minorities in ACTG, HPTN and VTN clinical trials at the UCLA-APT-CTU.
|Grinsztejn, Beatriz; Hosseinipour, Mina C; Ribaudo, Heather J et al. (2014) Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 14:281-90|
|Asmelash, Aida; Zheng, Yu; Kaloustian, Kara Wools et al. (2014) Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa. BMC Infect Dis 14:331|
|Lennox, Jeffrey L; Landovitz, Raphael J; Ribaudo, Heather J et al. (2014) Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 161:461-71|
|Leger, Paul D; Johnson, Daniel H; Robbins, Gregory K et al. (2014) Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. J Neurovirol 20:304-8|
|Wyatt, Christina M; Kitch, Douglas; Gupta, Samir K et al. (2014) Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr 67:36-44|
|Zheng, Yu; Hughes, Michael D; Lockman, Shahin et al. (2014) Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis 59:888-96|
|Haas, David W; Kwara, Awewura; Richardson, Danielle M et al. (2014) Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J Antimicrob Chemother 69:2175-82|
|Harawa, N; Wilton, L; Wang, L et al. (2014) Types of female partners reported by black men who have sex with men and women (MSMW) and associations with intercourse frequency, unprotected sex and HIV and STI prevalence. AIDS Behav 18:1548-59|
|Harezlak, J; Cohen, R; Gongvatana, A et al. (2014) Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART. J Neurovirol 20:294-303|
|Piwowar-Manning, Estelle; Fogel, Jessica M; Laeyendecker, Oliver et al. (2014) Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening. HIV Clin Trials 15:62-8|
Showing the most recent 10 out of 22 publications